BridgeBio Pharma (BBIO) Free Cash Flow Growth (3y) (2021 - 2026)
BridgeBio Pharma (BBIO) Free Cash Flow Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,981.90 Bn | 66,981.62 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,930.48 Bn | 1,930.42 Bn | - | - |
| 3 | Akari Therapeutics | 1,071.19 Bn | 1,071.19 Bn | - | - |
| 4 | BeOne Medicines | 468.55 Bn | 463.76 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 123.04 Bn | 115.79 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.31 Bn | 61.56 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 63.40 Bn | 63.40 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.67 Bn | 34.66 Bn | 959.66 Mn | 31.42% |
| 10 | BridgeBio Pharma | 16.64 Bn | 15.70 Bn | 184.58 Mn | -10.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.99% |
| Dec 31, 2025 | 16.28% |
| Sep 30, 2025 | 6.01% |
| Jun 30, 2025 | -34.77% |
| Mar 31, 2025 | -7.28% |
| Dec 31, 2024 | -10.52% |
| Sep 30, 2024 | -14.71% |
| Jun 30, 2024 | 40.94% |
| Mar 31, 2024 | -13.02% |
| Dec 31, 2023 | -11.13% |
| Sep 30, 2023 | -3.11% |
| Jun 30, 2023 | -8.86% |
| Mar 31, 2023 | -17.75% |
| Dec 31, 2022 | -7.93% |
| Sep 30, 2022 | -37.85% |
| Jun 30, 2022 | 21.57% |
| Mar 31, 2022 | -39.41% |
| Dec 31, 2021 | -45.31% |
| Sep 30, 2021 | -45.44% |